| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Exchange differences on translation | 76,842 | |||
| Research and development | 3,668,738 | |||
| General and administrative | 4,242,828 | |||
| Loss from operations | -7,911,566 | |||
| Reimbursement grant income | 783,894 | |||
| Interest income | 2,558 | |||
| Misc other income | 0 | |||
| Foreign exchange loss | -59,609 | |||
| Nonoperating income (expense) | 726,843 | |||
| Loss before income taxes | -7,184,723 | |||
| Income tax expense | 800 | |||
| Net loss | -7,200,000 | |||
| Net comprehensive loss | -7,100,000 | |||
| Loss per common share - basic and diluted (in dollars per share) | -1.27 | |||
| Weighted average number of common shares (in shares) | 5,676,708 | |||
Edesa Biotech, Inc. (EDSA)
Edesa Biotech, Inc. (EDSA)